New HIV/AIDS vaccine enters phase II trials
The US National Institute of Allergy and Infectious Diseases (NIAID) and pharmaceutical company Merck have begun enrolling around 1500 people at high risk of contracting HIV in a multicountry phase II trial of an investigational HIV/AIDS vaccine. The vaccine uses an adenovirus—a common cold virus—for the delivery of three synthetic HIV genes, gag, pol, and nef, into cells.
Lancet Infectious Diseases
(2005). New HIV/AIDS vaccine enters phase II trials. Lancet Infectious Diseases, 5(3), 138.
Available at: https://ecommons.aku.edu/pakistan_fhs_mc_surg_surg/444